|
EP0711804A3
(de)
|
1994-11-14 |
1999-09-22 |
Ciba SC Holding AG |
Kryptolichtschutzmittel
|
|
JP3512911B2
(ja)
|
1995-07-11 |
2004-03-31 |
富士写真フイルム株式会社 |
紫外線吸収剤前駆体化合物、それを含有する感光性樹脂組成物及び画像形成方法
|
|
KR100563514B1
(ko)
|
1997-07-24 |
2006-03-27 |
젠야쿠코교가부시키가이샤 |
헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제
|
|
JPH11174638A
(ja)
|
1997-12-08 |
1999-07-02 |
Konica Corp |
ハロゲン化銀カラー写真感光材料
|
|
ES2788383T3
(es)
|
2000-04-25 |
2020-10-21 |
Icos Corp |
Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
|
|
US6777439B2
(en)
|
2000-05-30 |
2004-08-17 |
Advanced Research & Technology Institute, Inc. |
Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
|
|
EP1389617B1
(en)
|
2001-04-27 |
2007-01-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
|
DE10207037A1
(de)
|
2002-02-20 |
2003-08-28 |
Bayer Cropscience Gmbh |
2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
|
|
EP1485100B1
(en)
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles as inhibitors of protein kinases
|
|
DE60327999D1
(de)
|
2002-03-15 |
2009-07-30 |
Vertex Pharma |
Azolylaminoazine als inhibitoren von proteinkinasen
|
|
AU2003218215A1
(en)
|
2002-03-15 |
2003-09-29 |
Vertex Pharmaceuticals, Inc. |
Azolylaminoazines as inhibitors of protein kinases
|
|
WO2003078423A1
(en)
|
2002-03-15 |
2003-09-25 |
Vertex Pharmaceuticals, Inc. |
Compositions useful as inhibitors of protein kinases
|
|
CN1668759A
(zh)
|
2002-05-17 |
2005-09-14 |
协和发酵工业株式会社 |
具有抗糖尿病作用的物质的探索方法
|
|
KR101046015B1
(ko)
|
2002-10-25 |
2011-07-01 |
젠야쿠코교가부시키가이샤 |
헤테로고리 화합물 및 이것을 유효성분으로 하는 항종양제
|
|
US7423148B2
(en)
|
2002-11-21 |
2008-09-09 |
Chiron Corporation |
Small molecule PI 3-kinase inhibitors and methods of their use
|
|
WO2005028467A1
(en)
|
2003-09-15 |
2005-03-31 |
Anadys Pharmaceuticals, Inc. |
Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
|
|
NZ546058A
(en)
|
2004-01-12 |
2010-09-30 |
Ym Biosciences Australia Pty |
Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
|
|
CA2561406C
(en)
|
2004-03-31 |
2012-07-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and anti-malignant-tumor agent comprising the same as effective component
|
|
ME01309B
(me)
|
2004-08-26 |
2013-12-20 |
Pfizer |
Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
|
|
WO2006053109A1
(en)
|
2004-11-10 |
2006-05-18 |
Synta Pharmaceuticals Corp. |
Heteroaryl compounds
|
|
EP1819341A4
(en)
|
2004-11-10 |
2011-06-29 |
Synta Pharmaceuticals Corp |
IL-12 MODULATORY CONNECTIONS
|
|
TWI381841B
(zh)
|
2005-03-11 |
2013-01-11 |
Zenyaku Kogyo Kk |
An immunosuppressive agent and an antitumor agent containing a heterocyclic compound as an active ingredient
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
GB0525081D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US20070244110A1
(en)
|
2006-04-14 |
2007-10-18 |
Zenyaku Kogyo Kabushiki Kaisha |
Treatment of prostate cancer, melanoma or hepatic cancer
|
|
CN101511840A
(zh)
|
2006-04-26 |
2009-08-19 |
吉宁特有限公司 |
磷酸肌醇3-激酶抑制剂化合物及其使用方法
|
|
TWI498332B
(zh)
|
2006-04-26 |
2015-09-01 |
Hoffmann La Roche |
作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
|
|
DK2050749T3
(en)
|
2006-08-08 |
2018-01-08 |
Chugai Pharmaceutical Co Ltd |
PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
|
|
CN101595103A
(zh)
|
2006-09-14 |
2009-12-02 |
阿斯利康(瑞典)有限公司 |
嘧啶衍生物
|
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JP2010503651A
(ja)
|
2006-09-14 |
2010-02-04 |
アストラゼネカ アクチボラグ |
増殖性障害の治療用のＰＩ３Ｋ及びｍＴＯＲ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−フェニルピリミジン誘導体
|
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
EP2069330A1
(en)
|
2006-09-14 |
2009-06-17 |
AstraZeneca AB |
2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032041A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives having inhibitory activity against pi3k enzymes
|
|
WO2008032072A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008098058A1
(en)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Pi 3-kinase inhibitors and methods of their use
|
|
WO2008110891A2
(en)
|
2007-03-09 |
2008-09-18 |
Orchid Research Laboratories Limited, |
New heterocyclic compounds
|
|
US20080233127A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
|
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
|
AU2008262291A1
(en)
|
2007-06-11 |
2008-12-18 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
|
WO2009007751A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
EP2209785A1
(en)
|
2007-10-05 |
2010-07-28 |
S*BIO Pte Ltd |
2-morpholinylpurines as inhibitors of pi3k
|
|
BRPI0817503B8
(pt)
|
2007-10-05 |
2021-05-25 |
Sstarbio Pte Ltd |
derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
|
|
TWI482768B
(zh)
|
2007-11-22 |
2015-05-01 |
Zenyaku Kogyo Kk |
雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
WO2009093981A1
(en)
|
2008-01-23 |
2009-07-30 |
S Bio Pte Ltd |
Triazine compounds as kinase inhibitors
|
|
US20090192176A1
(en)
|
2008-01-30 |
2009-07-30 |
Wyeth |
1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
|
|
TW200938201A
(en)
|
2008-02-07 |
2009-09-16 |
Chugai Pharmaceutical Co Ltd |
Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
|
|
EP2276750A2
(en)
|
2008-03-27 |
2011-01-26 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
|
AP2775A
(en)
|
2008-05-23 |
2013-09-30 |
Wyeth Llc |
Triazine compounds as P13 kinase and MTOR inhibitors
|
|
EP2310391A1
(en)
|
2008-06-27 |
2011-04-20 |
S*BIO Pte Ltd |
Pyrazine substituted purines
|
|
JP2011527342A
(ja)
|
2008-07-07 |
2011-10-27 |
エックスカバリー ホールディング カンパニー エルエルシー |
Ｐｉ３ｋアイソフォーム選択的阻害剤
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
CN102271683B
(zh)
|
2008-11-13 |
2014-07-09 |
吉里德卡利斯托加公司 |
恶性血液病的治疗
|
|
US20120165309A1
(en)
|
2009-02-12 |
2012-06-28 |
Astellas Pharma Inc. |
Hetero ring derivative
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
SG174527A1
(en)
|
2009-03-27 |
2011-11-28 |
Pathway Therapeutics Inc |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
CA2772371A1
(en)
|
2009-05-27 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
|
|
CN102459272B
(zh)
|
2009-05-27 |
2014-08-06 |
健泰科生物技术公司 |
对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
|
|
EP2445902A2
(en)
|
2009-06-25 |
2012-05-02 |
Amgen, Inc |
Heterocyclic compounds and their uses as inhibitors of pi3k activity
|
|
EA201270013A1
(ru)
|
2009-06-25 |
2012-06-29 |
Амген Инк. |
Гетероциклические соединения и их применение
|
|
CN102625799A
(zh)
|
2009-06-25 |
2012-08-01 |
安姆根有限公司 |
杂环化合物及其用途
|
|
WO2010151735A2
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
|
US8486939B2
(en)
|
2009-07-07 |
2013-07-16 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
KR101759762B1
(ko)
|
2010-08-10 |
2017-07-19 |
아스텔라스세이야쿠 가부시키가이샤 |
헤테로환 화합물
|
|
EP2648676A4
(en)
|
2010-12-06 |
2016-05-04 |
Follica Inc |
METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
|
|
WO2012129562A2
(en)
|
2011-03-24 |
2012-09-27 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
ES2608967T3
(es)
|
2011-03-28 |
2017-04-17 |
Mei Pharma, Inc. |
(Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
|
|
WO2012135166A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
JP2014509648A
(ja)
|
2011-03-28 |
2014-04-21 |
メイ プハルマ，インコーポレーテッド |
（α−置換シクロアルキルアミノ及びヘテロシクリルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
|
|
WO2012178124A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2723745A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013006408A1
(en)
|
2011-07-01 |
2013-01-10 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
|
EP2776386B1
(de)
|
2011-11-11 |
2019-11-20 |
Merck Patent GmbH |
Verfahren zur herstellung von arylaminen
|
|
BR112015002285B1
(pt)
|
2012-08-09 |
2022-05-10 |
Celgene Corporation |
Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
SG11201503393SA
(en)
*
|
2012-11-02 |
2015-06-29 |
Tg Therapeutics Inc |
Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
|
|
US9963452B2
(en)
|
2013-03-14 |
2018-05-08 |
Augusta Pharmaceuticals Inc. |
Methods, compounds, and compositions for inhibition of ROS
|
|
EP2832358A1
(en)
|
2013-08-02 |
2015-02-04 |
Bionsil S.r.l. |
Pharmaceutical kit for use in the treatment of colon and colorectal cancer
|
|
EA201691169A1
(ru)
|
2013-12-05 |
2016-09-30 |
Асерта Фарма Б.В. |
Терапевтическая комбинация ингибитора pi3k и ингибитора btk
|
|
EP3102238A1
(en)
*
|
2014-01-20 |
2016-12-14 |
Gilead Sciences, Inc. |
Therapies for treating cancers
|
|
AU2015220427B2
(en)
|
2014-02-19 |
2017-09-21 |
Piramal Enterprises Limited |
Compounds for use as GPR120 agonists
|
|
US9949971B2
(en)
|
2014-06-17 |
2018-04-24 |
Acerta Pharma B.V. |
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
|
|
MA40596B1
(fr)
|
2014-08-11 |
2021-12-31 |
Acerta Pharma Bv |
Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
|
|
WO2016024227A1
(en)
|
2014-08-11 |
2016-02-18 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
|
AU2015367977B9
(en)
|
2014-12-24 |
2020-02-06 |
Lg Chem, Ltd |
Biaryl derivative as GPR120 agonist
|
|
AR105392A1
(es)
|
2015-07-20 |
2017-09-27 |
Genzyme Corp |
Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
|
|
WO2017035234A1
(en)
|
2015-08-24 |
2017-03-02 |
Epizyme, Inc. |
Method for treating cancer
|
|
WO2017066705A1
(en)
|
2015-10-14 |
2017-04-20 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use against stress granules
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
|
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
US11304953B2
(en)
|
2017-05-23 |
2022-04-19 |
Mei Pharma, Inc. |
Combination therapy
|
|
KR20200041358A
(ko)
|
2017-08-14 |
2020-04-21 |
메이 파마, 아이엔씨. |
병용 요법
|
|
EP3768258A4
(en)
|
2018-03-21 |
2022-01-12 |
MEI Pharma, Inc. |
COMBINATION THERAPY
|
|
AU2019321526A1
(en)
|
2018-08-14 |
2021-03-25 |
Mei Pharma, Inc. |
Treatment of relapsed follicular lymphoma
|
|
MX2021001606A
(es)
|
2018-08-14 |
2021-04-19 |
Mei Pharma Inc |
Tratamiento de la malignidades de las celulas b.
|
|
WO2020132563A1
(en)
|
2018-12-21 |
2020-06-25 |
Mei Pharma, Inc. |
Combination therapy
|